Clifford Samuel, Principal at PCMS1 Consulting, advises large caps, start-ups, and NGOs on access and distribution of life-saving medicines in emerging and low-/middle-income markets. He brings 30+ years of biopharma leadership, including over two decades at Gilead Sciences in senior roles spanning sales, managed markets, and global operations.

At Gilead, Clifford served as SVP, Global Patient Solutions (2007–2020), overseeing 140+ countries and building partnerships with governments, NGOs, and generics manufacturers to expand access to HIV, hepatitis B & C, and COVID-19 medicines—ultimately reaching more than 19 million patients worldwide. He pioneered Gilead’s landmark voluntary licensing agreements in South Africa, India, and Pakistan, creating competitive generic markets in resource-limited regions.

Clifford currently consults on biopharma investment opportunities, early-stage clinical studies, and go-to-market strategies in complex global markets. In 2022, he was awarded a fellowship at Harvard’s Berkman Klein Center to study voluntary licensing and access during pandemics. He is a Fellow of AIMBE, a Board member of Antiva Biosciences and MTV Staying Alive Foundation, and an advisor to Siolta Therapeutics, Pardes Biosciences, and Karkinos Healthcare (India).

A graduate of NJIT (BS, Mechanical Engineering), Clifford received an Honorary PhD from his alma mater, the Edward F. Weston Medal for Professional Achievement, and induction into the National Academy of Engineering in 2019.

Back